Nucleus
Nucleus provides DTC genetic analysis of greater breadth, depth, and clarity
Top Tier Investor
Overview
Nucleus is building a DTC genetic testing platform that provides innovative genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS).
Nucleus provides WGS genetic testing kits for users to receive rare variant analysis and polygenic scores across a wide variety of diseases and traits — ranging from breast cancer risk to longevity disposition. Individuals who have done DTC microarray genetic testing from companies such as 23andMe can upload their genotyped DNA on the Nucleus platform to receive a subset of the possible genetic analyses, centering around polygenic scores. These scores are calculated by combining the effects of hundreds, thousands, or even millions of DNA letters that vary from one individual to another.
Nucleus provides WGS genetic testing kits for users to receive rare variant analysis and polygenic scores across a wide variety of diseases and traits — ranging from breast cancer risk to longevity disposition. Individuals who have done DTC microarray genetic testing from companies such as 23andMe can upload their genotyped DNA on the Nucleus platform to receive a subset of the possible genetic analyses, centering around polygenic scores. These scores are calculated by combining the effects of hundreds, thousands, or even millions of DNA letters that vary from one individual to another.
Industries
Biotechnology
